Lead Product(s) : Tofogliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Kowa Company
Deal Size : Inapplicable
Deal Type : Inapplicable
TOFO Insulin Combination Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2014
Lead Product(s) : Tofogliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Kowa Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofogliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Kowa Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2022
Lead Product(s) : Tofogliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Kowa Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofogliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase IV
Sponsor : Kowa Company
Deal Size : Inapplicable
Deal Type : Inapplicable
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2016
Lead Product(s) : Tofogliflozin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Sponsor : Kowa Company
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofogliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Tofogliflozin GLP-1 Analogue Combination Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2015
Lead Product(s) : Tofogliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofogliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2010
Lead Product(s) : Tofogliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable